03-09.06 U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE RLL-259US TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/523,207 CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/IB2002/002940 7 /29/2002 TITLE OF INVENTION OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS APPLICANT(S) FOR DO/EO/US MEHTA, et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.  $\boxtimes$ This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below. The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a.. 🗆 is attached hereto. b. 🗆 has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) are attached hereto (required only if not communicated by the International Bureau). b. 🗆 have been communicated by the International Bureau. c. 🗆 have not been made; however, the time limit for making such amendments has NOT expired. d. 🗆 have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 

2.

3.

4.

5.

7.

8.

9.

10.

11.

Article 36 (35 U.S.C. 371 (c)(5)).

12. A copy of the International Search Report (PCT/ISA/210). Items 13 to 23 below concern document(s) or information included:  $\boxtimes$ 13. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14. 15. A FIRST preliminary amendment. 16. A SECOND or SUBSEQUENT preliminary amendment. 17. A substitute specification. 18. A power of attorney and/or change of address letter. 19 A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 20 A second copy of the published International Application under 35 U.S.C. 154(d)(4). 21. A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).  $\times$ 22. Express Mail Label No. EV 483375923 US

An English language translation of the annexes to the International Preliminary Examination Report under PCT

A copy of the International Preliminary Examination Report (PCT/IPEA/409).

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO (if known, see 37 CFR 1.5)		) INTERNATIONAL	INTERNATIONAL APPLICATION NO.			ATTORNEY'S DOCKET NUMBER			
10/523,207			PCT/IB2002/002940			RLL-259US			
23. Other items or information:									
			·			<u> </u>	· · · · · · · · · · · · · · · · · · ·		
	g fees have been s	CALCULATIONS	PTO USE						
24. D Basic n	ational fee	\$ \$0.00							
	ation fee (37 CFR alon prepared by IS	\$ \$0.00							
prepared by IPE	VUS indicates all c	3(1)-(4). \$0	ψ ψ0.00						
					\$200				
If the written opin		r the Intern	ational preliminary exan						
			rovisions of PCT Article d on the international ap			\$ \$0.00			
as an Inter	national Searching	Authority.		·	\$100				
international Sea previously	rcn κepoπ prepare communicated to t	he US by th	A other than the US and ne IB	prov	\$400				
				· · · <u>· ·</u>	\$500	g g0 00			
— Additional fe	L OF 24, 25 and ee for specification	26 = and drawin	as filed in paper over 10	0 she	eets (excluding	\$ \$0.00			
sequence lis	sting in compliance inic medium) (37 C	with 37 CF FR 1.492(j	gs filed in paper over 10 R 1.821(c) or (e) or com )). eets of paper or fraction	pute	program listing				
The fee is \$2	250 for each àddition								
Total Sheets	Extra Sheets		er of each additional 50 on thereof (round <b>up</b> to a wh		RATE				
- 100 =	0 /50 =		0		x \$250.00	\$ \$0.00			
	0.00 for furnishing the date of comme	\$							
CLAIMS	NUMBER F	ILED	NUMBER EXTRA		RATE				
Total claims		- 20 =	0	х	\$50.00	\$ \$0.00			
Independent clair	ms	- 3=	0	х	\$200.00	\$ \$0.00			
MULTIPLE DEPENDENT CLAIMS (if applicable)						\$ \$0.00			
		\$ \$0.00							
☐ Applicant cla	aims small entity st	\$ \$0.00							
		\$ \$0.00							
	f <b>\$130.00</b> for furnis ed priority date (37	\$ \$0.00							
		\$ \$0.00							
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +						\$ \$0.00			
TOTAL FEES ENCLOSED =						\$ \$0.00			
						Amount to be	\$		
						Amount to be	\$		

,•				U.S. Patent and Trademark 0	PTO-1390 (Rev. 07-2005 I for use through 3/31/2007. OMB 0651-0021 Office; U.S. DEPARTMENT OF COMMERCE				
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.									
а. [	A check	in the amount of \$	to cover the	ne above fees is enclosed.					
b. [		harge my Deposit Accou		in the amount of \$	to cover the above fees.				
с. [2	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No A duplicate copy of this sheet is enclosed.								
d. [	d. Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit card</b> information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.									
SEN	D ALL CORF	RESPONDENCE TO:		Wattle	ut tave				
Cust	tomer No. 20	6815		SIGNATURE					
				William D. H	Iare, Esq.				
				NAME	3				
				44,739					
				REGISTRATIO	N NUMBER				
				March 8, 200	06				
				DATE					

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

MEHTA et al.

International Application No.:

PCT/IB2002/002940

Filing Date:

July 29, 2002

Title:

OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS

## **CERTIFICATE OF EXPRESS MAILING**

I hereby certify that the following correspondence:

- Transmittal Letter to the US/DO/EO Concerning a Filing Under 35 USC 371 (SECCOND SUBMISSION)
- Transmittal of Information Disclosure Statement
- Information Disclosure Citation (with References)
- Postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on March 8, 2006.

Michelle Morgan
Name of Person Mailing Correspondence

Signature

EV 483375923US

"Express Mail" Mailing Label Number